Gus Alva

756 total citations
12 papers, 424 citations indexed

About

Gus Alva is a scholar working on Psychiatry and Mental health, Neurology and Physiology. According to data from OpenAlex, Gus Alva has authored 12 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 3 papers in Neurology and 3 papers in Physiology. Recurrent topics in Gus Alva's work include Schizophrenia research and treatment (5 papers), Parkinson's Disease Mechanisms and Treatments (3 papers) and Tryptophan and brain disorders (2 papers). Gus Alva is often cited by papers focused on Schizophrenia research and treatment (5 papers), Parkinson's Disease Mechanisms and Treatments (3 papers) and Tryptophan and brain disorders (2 papers). Gus Alva collaborates with scholars based in United States, Canada and Switzerland. Gus Alva's co-authors include Steven G. Potkin, D. Carreon, James L. Kennedy, Yi Jin, Vincenzo S. Basile, Mario Masellis, Xiangyi Meng, W.E. Bunney, Fabìo Macciardi and W. Kalow and has published in prestigious journals such as Molecular Psychiatry, Schizophrenia Bulletin and Schizophrenia Research.

In The Last Decade

Gus Alva

12 papers receiving 413 citations

Peers

Gus Alva

PMH

NEURO

CN

PHARM

CMN

Martin Ebinger Germany

Amitabh Dash Japan

Iván Tellado Spain

Joachim Scharfetter Austria

Elena G. Kornetova Russia

Louis R. Ptak United States

Kazunori Kawakami Japan

Kazuto Oya Japan

Г. Г. Симуткин Russia

M Maggini Italy

Martin Ebinger Germany

Gus Alva

123 ×0.5

PMH

30 ×0.3

NEURO

45 ×0.5

CN

66 ×0.8

PHARM

39 ×0.6

CMN

Citations per year, relative to Gus Alva Gus Alva (= 1×) peers Martin Ebinger

Countries citing papers authored by Gus Alva

Since Specialization

Citations

This map shows the geographic impact of Gus Alva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gus Alva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gus Alva more than expected).

Fields of papers citing papers by Gus Alva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gus Alva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gus Alva. The network helps show where Gus Alva may publish in the future.

Co-authorship network of co-authors of Gus Alva

This figure shows the co-authorship network connecting the top 25 collaborators of Gus Alva. A scholar is included among the top collaborators of Gus Alva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gus Alva. Gus Alva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Alva, Gus, et al.. (2024). Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study. Journal of Alzheimer s Disease. 98(1). 265–274. 5 indexed citations

2.

Alva, Gus, Jeffery L. Cummings, James E. Galvin, Xingqiong Meng, & Drew M. Velting. (2015). Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. International Journal of Clinical Practice. 69(5). 518–530. 15 indexed citations

3.

Weiden, Peter J., Leslie Citrome, Gus Alva, et al.. (2014). A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia Research. 153(1-3). 160–168. 16 indexed citations

4.

Citrome, Leslie, Peter J. Weiden, Gus Alva, et al.. (2014). Switching to Iloperidone. Clinical Schizophrenia & Related Psychoses. 8(4). 183–195. 6 indexed citations

5.

Shankle, William R., et al.. (2012). Hierarchical Bayesian cognitive processing models to analyze clinical trial data. Alzheimer s & Dementia. 9(4). 422–428. 5 indexed citations

6.

Farlow, Martin R., Gus Alva, Xiangyi Meng, & Jason T. Olin. (2009). A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Current Medical Research and Opinion. 26(2). 263–269. 46 indexed citations

7.

Potkin, Steven G., Gus Alva, İbrahim Günay, et al.. (2006). A Pilot Study Evaluating the Efficacy and Safety of Rivastigmine in Patients with Mixed Dementia. Drugs & Aging. 23(3). 241–249. 14 indexed citations

8.

Jin, Yi, Steven G. Potkin, Aaron S. Kemp, et al.. (2005). Therapeutic Effects of Individualized Alpha Frequency Transcranial Magnetic Stimulation ( TMS) on the Negative Symptoms of Schizophrenia. Schizophrenia Bulletin. 32(3). 556–561. 99 indexed citations

9.

Potkin, Steven G., Vincenzo S. Basile, Yi Jin, et al.. (2003). D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Molecular Psychiatry. 8(1). 109–113. 84 indexed citations

10.

Potkin, Steven G., Gus Alva, John Panagides, et al.. (2003). Predicting Clinical Antipsychotic Doses from Preclinical and PET studies: A Case Study with Asenapine. 1 indexed citations

11.

Potkin, Steven G., et al.. (2003). EEG-guided RTMS improves negative symptoms in schizophrenia. Schizophrenia Research. 60(1). 287–288. 2 indexed citations

12.

Basile, Vincenzo S., Vural Özdemir, Mario Masellis, et al.. (2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular Psychiatry. 5(4). 410–417. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact